Dianicline (SSR-591,813) is a drug developed by
Sanofi-Aventis which acts as a
partial agonist at neural
nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the
α4β2subtype. It is being developed as a medication for the treatment of
nicotine dependence to assist in
smoking cessation.[1] Dianicline is very similar to the already marketed drug
varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials.[2][3][4]
References
^Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, et al. (July 2003). "SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 407–20.
doi:
10.1124/jpet.103.049262.
PMID12682217.
S2CID37543790.
^Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs. 2006; 15(2):107-116.